Skip to main content

Table 5 Bleeding Characteristic

From: High rate of bleeding and arterial thrombosis in COVID-19: Saudi multicenter study

Age

ICU

Site of bleeding

Severity

Anticoagulant at time of bleeding

45

Yes

Lung

Major

UFH 5000 IU TID

62

Yes

Lower GI

Major

Enoxaparin 40 mg once

62

Yes

Hematuria

Non major

Aspirin

61

Yes

Cutaneous

Non major

UFH 5000 IU TID

73

Yes

CNS

Major

Enoxaparin 40 mg once

64

Yes

Cutaneous

Non major

Enoxaparin 40 mg once

59

Yes

Cutaneous

Non major

Enoxaparin 40 mg once

62

No

Musculoskeletal

Major

Enoxaparin 40 mg once

31

Yes

CNS

Major

Enoxaparin 40 mg once

74

Yes

Cutaneous

Non major

Enoxaparin 40 mg BID

41

Yes

Lower GI

Non major

Full dose UFH